信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE

The board (the "**Board**") of Directors (the "**Directors**", each a "**Director**") of Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that with effect from August 26, 2025, Dr. Stephen A. Sherwin ("**Dr. Sherwin**") has been appointed as an independent non-executive Director and a member of the strategy committee of the Board.

The biographical details of Dr. Sherwin are set out below:

Dr. Stephen A. Sherwin

Dr. Stephen A. Sherwin, aged 76, currently engages in advisory work in the life science industry and patient care and teaching in medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. In his advisory work, Dr. Sherwin has been serving as an advisory partner at Third Rock Ventures since 2016, a director of Biogen (Nasdaq: BIIB) since 2010 and a director of Neurocrine Biosciences (Nasdaq: NBIX) since 1999. He is also an advisor to the Parker Institute for Cancer Immunotherapy. Previously Dr. Sherwin was chairman and chief executive officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company's merger in 2009 with ANI Pharmaceuticals. He was also co-founder and chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of vice president, and prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011.

Dr. Sherwin received his bachelor of arts degree in biology from Yale University in 1970 and doctor of medicine degree from Harvard Medical School in 1974. He is board-certified in internal medicine and medical oncology, a member of American Society of Clinical Oncology, a member of American Association of Cancer Research and a fellow of the American College of Physicians.

Dr. Sherwin has entered into a letter of appointment with the Company for a term of three years commencing on August 26, 2025 and continue thereafter until terminated by either party by giving at least three months' notice in writing. Dr. Sherwin is subject to retirement by rotation and re-election at the forthcoming annual general meeting in accordance with the memorandum and articles of association of the Company and the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Pursuant to the letter of appointment, Dr. Sherwin shall be entitled to receive a director's fees of RMB400,000 per annum, which has been determined by the Board upon recommendation of the remuneration committee of the Company with reference to his experience and duties with the Company and prevailing market conditions.

Save as disclosed above, as at the date of this announcement, (i) Dr. Sherwin does not hold any other position in the Company or its subsidiaries; (ii) Dr. Sherwin does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) Dr. Sherwin does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; (iv) Dr. Sherwin does not have any relationship with any Directors, senior management, substantial shareholders (as defined under the Listing Rules) or controlling shareholders (as defined under the Listing Rules) of the Company; and (v) Dr. Sherwin does not possess any other professional qualifications.

Dr. Sherwin has confirmed that (i) he meets the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Dr. Sherwin that need to be brought to the attention of the shareholders of the Company, nor is there any other information which is required to be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend a warm welcome to Dr. Sherwin on his appointment.

By order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
August 26, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as independent non-executive Directors.